Urticaria Pigmentosa

Subscribe to Selected New Research on Urticaria Pigmentosa

141 relevant articles (6 outcomes, 6 trials/studies) found for this Disease

Description: The most common form of cutaneous mastocytosis (MASTOCYTOSIS, CUTANEOUS) that occurs primarily in children. It is characterized by the multiple small reddish-brown pigmented pruritic macules and papules.

Also Known As:

Cutaneous Mastocytoses, Maculopapular; Cutaneous Mastocytosis, Maculopapular; Maculopapular Cutaneous Mastocytoses; Maculopapular Cutaneous Mastocytosis

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Neoplasms by Histologic Type: 1

Connective and Soft Tissue Neoplasms

Connective Tissue Neoplasms: 6

Mastocytosis: 442

Cutaneous Mastocytosis: 53

Urticaria Pigmentosa: 141

Skin and Connective Tissue Diseases

Skin Diseases: 5944

Mastocytosis: 442

Cutaneous Mastocytosis: 53

Urticaria Pigmentosa: 141

Pigmentation Disorders: 43

Urticaria Pigmentosa: 141

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema)
2.	Skin Diseases
3.	Granuloma Annulare
4.	Urticaria (Hives)
5.	Prurigo

Experts

1.	Jones, Evan: 1 article (06/2005)
2.	Resh, Brooke: 1 article (06/2005)
3.	Glaser, Dee Anna: 1 article (06/2005)
4.	Cork, Michael J: 1 article (09/2003)
5.	Bowling, Jonathan: 1 article (09/2003)
6.	Gharrie, S: 1 article (03/2000)
7.	Harland, C C: 1 article (03/2000)
8.	Bedlow, A J: 1 article (03/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Urticaria Pigmentosa:

1.	Histamine (Histamine Dihydrochloride)IBA 01/01/1981 - "These results suggest that this effective new treatment for urticaria pigmentosa reduces the histamine turnover in the skin by inhibiting mast cell proliferation." 05/01/1986 - "The possibility exists that several mediators and mechanisms superimpose during the early histamine-mediated phase of the vascular response in urticaria pigmentosa following activation of mast cells." 05/01/1986 - "Ultrastructure of the immediate, histamine-mediated microvascular response in human skin with urticaria pigmentosa." 07/01/1983 - "The beneficial effect of PUVA in urticaria pigmentosa therefore does not appear to be directly related to a change in mast cell numbers or morphology, or to the histamine concentration in the skin." 01/01/1981 - "Decreased urinary histamine metabolite after successful PUVA treatment of urticaria pigmentosa." Order ALL the reference details at left...
2.	Adrenal Cortex Hormones (Corticosteroids)IBA 09/01/1994 - "A case of adult-onset urticaria pigmentosa is presented, in which the eruption cleared following the application of potent topical corticosteroids" 01/01/1987 - "This led to the treatment of patients with urticaria pigmentosa with topical high potency corticosteroids for 6 weeks" 12/01/1985 - "Treatment of urticaria pigmentosa with corticosteroids." 11/01/1975 - "A patient had systemic mastocytosis of 16 years' duration, with urticaria pigmentosa, osteopetrosis with severe bone pain, mastocytosis of the bone marrow with myeloid metaplasia, gastrointestinal malabsorption, and Cushingold features associated with prolonged usage of corticosteroids" 12/01/1985 - "Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP)" Order ALL the reference details at left...
3.	Colloids (Colloid)IBA 11/01/1997 - "Prolonged remission of urticaria pigmentosa following topical steroid therapy under hydrocolloid occlusion." Order ALL the reference details at left...
4.	AntibodiesIBA 01/01/1985 - "Urticaria pigmentosa, steatorrhea, eosinophilia, absence of antireticulin antibodies, and submucosal nodularity seen on radiographic study of the duodenum were the clinical characteristics" 01/01/1997 - "These findings suggest that (1) anti-C5a receptor antibodies directed to the N-terminal domain of the receptor are suitable tools for the identification of mast cells in acrylate-embedded sections of human skin, (2) mast cell activation in weal and flare reactions results in C5a receptor downregulation or receptor blockade and (3) mast cells in urticaria pigmentosa lack a typical marker of normal human skin mast cells." 11/01/1990 - "Specific IgE antibodies to common inhalants were also observed less frequently in urticaria pigmentosa patients than in controls, although this difference was not statistically significant" 11/01/1990 - "Thirty-three patients with histologically verified urticaria pigmentosa were studied for coexisting atopic disease by means of history, skin prick testing with five common inhalants and serological investigation for total IgE and specific IgE antibodies to five common inhalants" 08/01/1995 - "In order to evaluate its possible role in human mastocytosis, skin lesions from 13 patients with urticaria pigmentosa and five patients with mastocytomas, and normal skin specimens from five healthy donors were studied by immunohistochemistry, using polyclonal and monoclonal (hkl-12) antibodies against stem cell factor, and a monoclonal antibody (YB5.B8) against its receptor, the c-kit proto-oncogene product" Order ALL the reference details at left...
5.	Substance PIBA 01/01/1998 - "The aim of our study was to evaluate the sensitivity of skin mast cells from urticaria pigmentosa (UP) patients to substance P (SP), tumor necrosis factor alpha (TNF-alpha) and anti-IgE, and to compare the sensitivity of these cells with that of skin mast cells from healthy human donors" 01/01/1993 - "Patients with urticaria pigmentosa were investigated during symptom-free interval regarding plasma concentrations and urinary excretion of immunoreactive regulatory peptides: calcitonin gene-related peptide (CGRP), gastrin, neurokinin A (NKA), neuropeptide Y (NPY), somatostatin (SOM), substance P (SP) and vasoactive intestinal peptide (VIP)" Order ALL the reference details at left...
6.	Histidine (L-Histidine)FDA Link 04/01/1961 - "Histidine metabolism in urticaria pigmentosa." 12/01/1961 - "Further studies of histidine and histamine metabolism in urticaria pigmentosa." Order ALL the reference details at left...
7.	tranilast (N 5')IBA 09/01/1998 - "To assess the diagnostic value of tryptase staining in mastocytosis, tissue sections from 93 patients with mastocytosis, including MM (n = 37), systemic indolent mastocytosis (n = 47), urticaria pigmentosa (n = 5), MC leukemia (n = 2), and solitary skin mastocytoma (n = 2) were stained with the antitryptase antibody G3" 07/01/1993 - "We have used the monoclonal antibody PC10 to study MCs in reactive or hyperplastic states (chronic non-specific lymphadenitis, n = 10; benign and malignant solid tumours, n = 5) and in the various subtypes of mastocytosis (urticaria pigmentosa, n = 22; solitary mastocytoma of the skin, n = 7; systemic mastocytosis; n = 8; malignant mastocytosis, n = 4)" Order ALL the reference details at left...
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/01/1998 - "The aim of our study was to evaluate the sensitivity of skin mast cells from urticaria pigmentosa (UP) patients to substance P (SP), tumor necrosis factor alpha (TNF-alpha) and anti-IgE, and to compare the sensitivity of these cells with that of skin mast cells from healthy human donors" Order ALL the reference details at left...
9.	UniversalIBA 08/01/1955 - "Pathogenesis of urticaria pigmentosa; studies of a case of universal mast cell reticulosis of the skin with pemphigold onset.]" Order ALL the reference details at left...
10.	mofezolac (N 22)IBA 07/01/1993 - "We have used the monoclonal antibody PC10 to study MCs in reactive or hyperplastic states (chronic non-specific lymphadenitis, n = 10; benign and malignant solid tumours, n = 5) and in the various subtypes of mastocytosis (urticaria pigmentosa, n = 22; solitary mastocytoma of the skin, n = 7; systemic mastocytosis; n = 8; malignant mastocytosis, n = 4)" Order ALL the reference details at left...

Therapies and Procedures

1.	Phototherapy (Light Therapy) 01/01/1985 - "Ten patients with moderate to very severe urticaria pigmentosa were studied for the therapeutic effect of photochemotherapy (PUVA; six adults) and selective ultraviolet phototherapy (SUP; four adolescents)" 12/01/2000 - "UVA1 phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such as acutely exacerbated atopic dermatitis, localized scleroderma, urticaria pigmentosa and disseminated granuloma annulare" 02/01/2008 - "OBJECTIVE: Investigation of the efficacy of ultraviolet (UV) A1 phototherapy on atopic eczema, scleroderma, granuloma annulare, urticaria pigmentosa, prurigo nodularis, lichen sclerosus et atrophicus, T-cell lymphoma, keratosis lichenoides chronica, chronic urticaria and some rare, sclerosing skin diseases" 01/01/1985 - "Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes." Order ALL the reference details at left...
2.	Solid-State Lasers 03/01/2000 - "We describe a 30-year-old woman with urticaria pigmentosa in whom treatment with the Nd:YAG laser produced a significant improvement in the clinical appearance of the eruption, with some recurrence after 9 months" 03/01/2000 - "The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser." 06/01/2005 - "Objective The purpose was to investigate the use of a diode-pumped Nd:YAG laser at 532 nm for the treatment of the cosmetic comorbidity of urticaria pigmentosa lesions" 06/01/2005 - "The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers." Order ALL the reference details at left...
3.	PUVA Therapy 10/01/2005 - "A 64-year-old man was diagnosed as having urticaria pigmentosa in 1998, and treated with PUVA therapy" 03/01/1980 - "This suggests that PUVA-therapy may exercise its beneficial effect in urticaria pigmentosa by direct destruction of these cells" 08/01/2001 - "After 18 months of intensive UVA1- and bath PUVA therapy for urticaria pigmentosa, a female patient developed a malignant melanoma on the right thigh" 01/01/1997 - "Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis." 01/01/1981 - "The effect of PUVA therapy on pruritus, the skin mast cell population and histamine metabolism has been studied in 3 patients with urticaria pigmentosa and manifestations of systemic mastocytosis" Order ALL the reference details at left...
4.	Photochemotherapy (Photodynamic Therapy) 07/01/1983 - "Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa." 01/01/1985 - "Ten patients with moderate to very severe urticaria pigmentosa were studied for the therapeutic effect of photochemotherapy (PUVA; six adults) and selective ultraviolet phototherapy (SUP; four adolescents)" 09/01/1984 - "In six patients with urticaria pigmentosa, population density and ultrastructure of the cutaneous mast cells and histamine levels of the lesional skin were studied before, immediately after, and again 5-8 months after photochemotherapy (PUVA)" Order ALL the reference details at left...
5.	Immunotherapy 07/01/1997 - "Venom immunotherapy can be safely and successfully used in patients with urticaria pigmentosa and sting anaphylaxis." 07/01/1997 - "METHODS: We investigated 10 patients with histologically confirmed urticaria pigmentosa and a history of anaphylaxis after honeybee or Vespula stings before and during immunotherapy with the respective venom" 07/01/1997 - "Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients." 11/01/2005 - "Besides the fact that the presence of urticaria pigmentosa alone could have explained the anaphylactic reaction to the aspecific stimulation triggered by the venom, this case history also demonstrates that omitting to perform skin tests for Polistes dominulus venom would have led to the same misdiagnosis of non IgE-mediated anaphylaxis and served only to further delay commencing specific immunotherapy." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Urticaria Pigmentosa

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 6 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>